Cor Lieftink
The Netherlands Cancer Institute · 271 works · 6,130 citations · h-index 34
Top works
- IntAct--open source resource for molecular interaction data
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- EGFR activation limits the response of liver cancer to lenvatinib
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- Inducing and exploiting vulnerabilities for the treatment of liver cancer
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
- High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
- RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
- A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
- Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer
- A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
- CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma
- FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
- A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma
- ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
- Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
- Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition
- A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma